研究と業績　2013年

研究と業績　2013年

英文

日野 雅之

  1. Nishimoto M, Nakamae H, Koh H, Nakane T, Nakamae M, Hirose A, Hagihara K, Nakao Y, Terada Y, Ohsawa M, Hino M. Risk factors affecting cardiac left-ventricular hypertrophy and systolic and diastolic function in the chronic phase of allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 48: 581-62, 2013
  2. Okamura H, Hayashi Y, Nakamae H, Shiomi S, Nishimoto M, Koh H, Nakane T, Hino M. Use of per rectal portal scintigraphy to detect portal hypertension in sinusoidal obstructive syndrome following unrelated cord blood transplantation. Acta Haematol 130, 83-86, 2013
  3. Kim SW, Yoon SS, Suzuki R, Matsuno Y, Yi HG, Yoshida T, Imamura M, Wake A, Miura K, Hino M, Ishikawa T, Kim JS, Maeda Y, Lee JJ, Kang HJ, Lee HS, Lee JH, Izutsu K, Fukuda T, Kim CW, Yoshino T, Ohshima K, Nakamura S, Nagafuji K, Suzumiya J, Harada M, Kim CS. Comparison of outcomes between autologous and allogeneic hematopoietic stem cell transplantation for peripheral T-cell lymphomas with central review of pathology. Leukemia 27:1394-1397, 2013
  4. Murata M, Nakasone H, Kanda J, Nakane T, Furukawa T, Fukuda T, Mori T, Taniguchi S, Eto T, Ohashi K, Hino M, Inoue M, Ogawa H, Atsuta Y, Nagamura-Inoue T, Yabe H, Morishima Y, Sakamaki H, Suzuki R. Clinical factors predicting the response of acute graft-versus-host disease to corticosteroid therapy. Biol Blood Marrow Transplant 19, 1183-1189, 2013
  5. Koh H, Hino M, Ohta K, Iino M, Urase F, Yamaguchi M, Yamanouchi J, Usui N, Yoshida M, Tanimoto M, Ohyashiki K, Urabe A, Tamura K, Kanamaru A, Masaoka T. Empirical voriconazole therapy for febrile neutropenic patients with hematological disorders: a prospective multicenter trial in Japan. J Infect ChemotherJ 19:1126-34, 2013
  6. Shinohara Y, Takahashi N, Nishiwaki K, Hino M, Kashimura M, Wakita H, Hatano Y, Hirasawa A, Nakagawa Y, Itoh K, Masuoka H, Aotsuka N, Matsuura Y, Takahara S, Sano K, Kuroki J, Hata T, Nakamae H, Mugitani A, Nakane T, Miyazaki Y, Niioka T, Miura M, Sawada K. A multicenter clinical study evaluating the confirmed complete molecular response rate in imatinib-treated patients with chronic phase chronic myeloid leukemia by using the international scale of real-time quantitative polymerase chain reaction. Haematologica. 98:1407-13, 2013
  7. Nishimoto M, Nakamae H, Kho K-R, Kosaka S, Matsumoto K, Morita K, Kho H, Nakane T, Ohsawa M, Hino M. Dasatinib maintenance therapy after allogeneic hematopoietic stem cell transplantation for isolated central nervous system blast crisis of chronic myelogenous leukemia. Acta Haematol 130:111-114, 2013
  8. Nakagawa Y, Suzuki K, Ohta K, Hino M, Ohyashiki K, Kanamaru A, Tamura K, Urabe A, Masaoka T. Prospective randomized study of cefepime, panipenem, or meropenem monotherapy for patients with hematological disorders and febrile neutropenia. J Infect Chemother 19:103-11, 2013
  9. Yoshimura T, Nakane T, Hirose A, Koh H, Nakamae M, Aimoto M, Nishimoto M, Hayashi Y, Terada Y, Nakamae H, Hino M. Prognostic factors and outcomes of unrelated bone marrow transplantation for Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) pre-treated with tyrosine kinase inhibitors. Osaka City Med J 59:9-21, 2013
  10. Nishimoto M, Nakamae H, Watanabe K, Koh H, Nakane T, Ohsawa M, Arakawa T, Hino M. Successful treatment of both acute leukemia and active Crohn's disease after allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning with fludarabine and busulfan: a case report. Transplant Proc 45:2854-2857, 2013
  11. Aimoto M, Yamane T, Shiomoto K, Sakamoto C, Nakashima Y, Koh H, Nakane T, Takeoka Y, Hirose A, Nakamae M, Hagihara K, Terada Y, Nakao Y, Nakamae H, Hino M, Miyata S. Refractoriness to platelet transfusion in acute myeloid leukemia correlated with the optical density of anti-platelet factor 4/heparin antibodies. Int J Hematol 98:472-477, 2013

工藤 新三

  1. Nagata M, Kudoh S, Mitsuoka S, Suzumura T, Umekawa K, Tanaka H, Matsuura K, Kimura T, Yoshimura N, Hirata KSkeletal-related events in advanced lung adenocarcinoma patients evaluated EGFR mutations. Osaka City Med J. 2013 Jun;59(1):45-522013
  2. Yoshimura N, Okishio K, Mitsuoka S, Kimura T, Kawaguchi T, Kobayashi M, Hirashima T, Daga H, Takeda K, Hirata K, Kudoh S Prospective assessment of continuation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of pemetrexed. J Thorac Oncol. 2013 Jan;8(1):96-101. 2013
  3. Yoshioka H, Okamoto I, Morita S, Ando M, Takeda K, Seto T, Yamamoto N, Saka H, Atagi S, Hirashima T, Kudoh S, Satouchi M, Ikeda N, Iwamoto Y, Sawa T, Nakanishi Y, Nakagawa K. Efficacy and safety analysis according to histology for S-1 in combination with carboplatin as first-line chemotherapy in patients with advanced non-small-cell lung cancer: updated results of the West Japan Oncology Group LETS study.Ann Oncol. 2013 Feb 4. [Epub ahead of print] 2013
  4. Nagata M, Kimura T, Suzumura T, Kira Y, Nakai T, Umekawa K, Tanaka H, Matsuura K, Mitsuoka S, Yoshimura N, Oka T, Kudoh S, Hirata K. C609T Polymorphism of NADPH Quinone Oxidoreductase 1 Correlates Clinical Hematological Toxicities in Lung Cancer Patients Treated with Amrubicin. Clin Med Insights Oncol. 2013;7:31-9. 2013
  5. Yoshimura N, Kimura T, Mitsuoka S, Kyoh S, Tochino Y, Asai K, Ichimaru Y, Hirata K, Kudoh S. Dose escalation and feasibility study of amrubicin combined with cisplatin in previously untreated patients with advanced non-small cell lung cancer. Am J Clin Oncol. 2013 Apr;36(2):105-9 2013
  6. Laporte S, Squifflet P, Baroux N, Fossella F, Georgoulias V, Pujol JL, Douillard JY, Kudoh S, Pignon JP, Quinaux E, Buyse M. Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials. BMJ Open. 2013 Mar 13;3(3) 2013
  7. Umekawa K, Kimura T, Kudoh S, Suzumura T, Oka T, Nagata M, Mitsuoka S, Matsuura K, Nakai T, Yoshimura N, Kira Y, Hirata K. Plasma RANTES, IL-10, and IL-8 levels in non-small-cell lung cancer patients treated with EGFR-TKIs. BMC Res Notes. 2013 Apr 8;6:139 2013
  8. Kogure Y, Ando M, Saka H, Chiba Y, Yamamoto N, Asami K, Hirashima T, Seto T, Nagase S, Otsuka K, Yanagihara K, Takeda K, Okamoto I, Aoki T, Takayama K, Yamasaki M, Kudoh S, Katakami N, Miyazaki M, Nakagawa K. Histology and smoking status predict survival of patients with advanced non-small-cell lung cancer. Results of West Japan Oncology Group (WJOG) Study 3906L. J Thorac Oncol. 2013 Jun;8(6):753-8.2013
  9. Umekawa K, Kimura T, Kudoh S, Suzumura T, Nagata M, Mitsuoka S, Matsuura K, Oka T, Yoshimura N, Kira Y, Hirata K Reaction of plasma adiponectin level in non-small cell lung cancer patients treated with EGFR-TKIs. Osaka City Med J. 2013 Jun;59(1):53-60.2013

川口 知哉

  1. Tomoya Kawaguchi, Masahiko Ando, Norimasa Ito, Shun-ichi Isa, Akihiro Tamiya, Shigeki Shimizu, Hideo Saka, Akihito Kubo, Yasuhiro Koh, Akihide Matsumura. Rationale and design of JME study: Japan Molecular Epidemiology for lung cancer study. Clinical Lung Cancer 14: 596-600, 2013
  2. Naruo Yoshimura, Kyoichi Okishio, Shigeki Mitsuoka, Tatsuo Kimura, Tomoya Kawaguchi, Masaji Kobayashi, Tomonori Hirashima, Haruko Daga, Koji Takeda, Kazuto Hirata and Shinzoh Kudoh. Prospective Assessment of Continuation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition of Pemetrexed. J Thoracic Oncol 8: 96-101, 2013

中尾 吉孝

  1. Nishimoto M. Nakamae H. Koh H. Nakane T. Nakamae M. Hirose A. Hagihara K. Nakao Y. Terada Y. Ohsawa M. Hino M. Risk factors affecting cardiac left-ventricular hypertrophy and systolic and diastolic function in the chronic phase of allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation. 2013;48:581-586.
  2. Aimoto M. Yamane T. Shiomoto K. Sakamoto C. Nakashima Y. Koh H. Nakane T. Takeoka Y. Hirose A. Nakamae M. Hagihara K. Terada Y. Nakao Y. Nakamae H. Hino M. Miyata S.Refractoriness to platelet transfusion in acute myeloid leukemia correlated with the optical 　density of anti-platelet factor 4/heparin antibodiesInt J Hematol. 2013 Oct;98(4):472-7.

吉村 成央

  1. Prospective assessment of continuation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of pemetrexed.共（筆頭）2013J ThoracOncol.8(1):96-101.
  2. Dose escalation and feasibility study of amrubicin combined with cisplatin in previously untreated patients with advanced non-small-cell lung cancer共（筆頭）2013Am J Clin Oncol. 36(2):105-9.

和文

日野 雅之

  1. 中前博久、西本光孝、徳和目篤史、日野雅之. 消化管急性移植片対宿主病に対するベクロメタゾンプロピオン酸エステル製剤の有効性. 臨床薬理の進歩 93-98, 2013
  2. 南野　智、中前博久、桑村幸信、石村栄治、坂部真奈美、稲葉晃子、康　史朗、吉村卓朗、西本光孝、林　良樹、寺田芳樹、中根孝彦、康　秀男、中尾吉孝、大澤政彦、日野雅之. 管内増殖性糸球体腎炎を合併した血管免疫芽球性T細胞性リンパ腫. 臨床血液　54:658-663, 2013
  3. 山村亮介、坂本恵利奈、寺田芳樹、阪本親彦、小坂さおり、青山泰孝、平井　学、太田健介、日野雅之. 輸血後鉄過剰症に対する経口鉄キレート剤(deferasirox)の使用経験. 日本輸血細胞治療学会誌 58:770-773, 2013
  4. 中前博久、中根孝彦、日野雅之. 造血幹細胞移植時の心筋障害. 田村和夫編　血液疾患治療に伴う合併症対策　医学ジャーナル社 pp 180-189, 2013
  5. 吉田全宏、金島　広、中尾隆文、小川吉彦、日野雅之、中根孝彦、太田忠信、 久村岳央、間部賢寛、山村亮介、山根孝久. エルトロンボパグを使用した難治性特発性血小板減少性紫斑病の後方視的検討. 臨床血液 54:444-450, 2013
  6. 南野　智、萩原潔通、坂部真奈美、岡村浩史、稲葉晃子、永田友貴、西本光孝、康　秀男、中尾吉孝、中根孝彦、中前博久、下野太郎、日野雅之. 中枢性尿崩症を合併した染色体-7とinv(3)(q21q26.2)を有する急性骨髄性白血病. 臨床血液 54:397-402, 2013
  7. 日野雅之、中前博久、梅本由香里. 末梢血幹細胞採取. 東條有伸編　G-CSFの基礎と臨床　医学ジャーナル社 pp 175-186, 2013
  8. 間部賢寛、西本光孝、伊藤和博、岡村浩史、備後真登、吉田全宏、井上敦司、相本瑞樹、林　良樹、康　秀男、中根孝彦、中前美佳、寺田芳樹、中前博久、中尾隆文、高　起良、平井　学、中尾吉孝、山根孝久、日野雅之. 同種骨髄移植後に急性横断性脊髄炎を合併した急性リンパ性白血病. 癌と化学療法 40:529-532, 2013
  9. 中村桂子、高島　勉、日野雅之、藤岡一也、武田節子、荻澤佳奈、川尻成美、小野田尚佳、石川哲郎、平川弘聖. 乳腺に再発した急性骨髄性白血病の2症例. Jpn J Med Ultrasonics 40,297-302, 2013

工藤 新三

  1. 樽井亜紀子、田原正恵、岡本綾子、李真由美、山崎仁美、中野妙子、高島勉、工藤新三抗がん剤の暴露予防の定着に向けた現状と課題 癌と化学療法 40、ｐ.1512-1524 2013

中尾 吉孝

  1. 中尾 吉孝, 松田 泰範, 下村 祥子, 鶴田 理恵, 柏木 伸一郎, 野田 諭, 小野田 尚佳, 平川 弘聖. 【甲状腺未分化癌の臨床】 甲状腺未分化癌の臨床像　緩和医療介入の実際. 日本内分泌・甲状腺外科学会雑誌 2013;30:182-186.
  2. 南野 智, 中前 博久, 桑村 幸伸, 石村 栄治, 坂部 真奈美, 稲葉 晃子, 康 史朗, 吉村 卓朗, 西本 光孝, 林 良樹, 寺田 芳樹, 中根 孝彦, 康 秀男, 中尾 吉孝, 大澤 政彦, 日野 雅之. 管内増殖性糸球体腎炎を合併した血管免疫芽球性T細胞性リンパ腫. 臨床血液 2013;54:658-663
  3. 南野 智, 萩原 潔通, 坂部 真奈美, 岡村 浩史, 稲葉 晃子, 永田 友貴, 西本 光孝, 康 秀男, 中尾 吉孝, 中根 孝彦, 中前 博久, 下野 太郎, 日野 雅之. 中枢性尿崩症を合併した染色体-7とinv(3)(q21q26.2)を有する急性骨髄性白血病. 臨床血液 2013;54:397-402